Skip to content
Home
Login
Sign up
Contact us
Search for:
General Information
Overview
Welcome Address
Organazing Committee
Venue
Registration
Registration Fee
Registration
Travel Grants
Guideline
Scientific Program
Abstract Submission
Guideline
Submission
Acceptance
Plan Your Trip
Accommodation
About Seoul
Useful Information
Sponsors & Exhibition
Submission
iass
2025-04-12T16:13:29+09:00
Submission
Submission Type
poster only
Country
Korea, Republic of
Name
LEO Pharma A/S
Email
HUELE@leo-pharma.com
Abstract Title
Long-term safety and efficacy of tralokinumab in patients 65 years or older with moderate-to-severe atopic dermatitis
File attachment
01-Blauvelt_fc24_65plus-encore.pdf
«
Unveiling the Role of Cannabinoid Receptor 2 in Atopic Dermatitis: A New Frontier in Cutaneous Immune Modulation
Stability of long-term therapeutic responses to tralokinumab in adults with moderate-to-severe atopic dermatitis
»
Edit
Delete
Close product quick view
×
Title
Page load link
Go to Top